Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Int J Psychophysiol. 2011 Jul 19;82(1):107–114. doi: 10.1016/j.ijpsycho.2011.06.022

Figure 1.

Figure 1

Group Activation Patterns during 2-Back in Response to Pharmacological Challenge

Activation maps (SPM5) for each group (MTBI and HC) under each drug condition (placebo or guanfacine). Note increased right frontal activation in the MTBI group on guanfacine when compared to placebo (1C and 1D).